Comparing MK-8748 to standard treatment for diabetic eye swelling
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a new medicine (MK-8748) against an existing treatment (aflibercept) for people with diabetic macular edema, which causes vision loss due to swelling in the back of the eye. The goal is to see which works better to improve or protect vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes with a recent blood sugar test (HbA1c) at 12% or lower.
- Vision loss in one eye is mainly from diabetic macular edema (swelling in the back of the eye).
- If you have not been treated for this eye condition before, your diagnosis must be within the last 9 months.
- If you have had prior treatment, it must have started no more than 3 years ago.
- You have no history of kidney failure requiring dialysis or transplant, and no recent stroke or heart attack (within 6 months).
- You have not had cataract or glaucoma surgery in the study eye within the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
Hear when a new Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.